- Topic
37k Popularity
50k Popularity
23k Popularity
666 Popularity
3k Popularity
5k Popularity
67k Popularity
139k Popularity
426 Popularity
1751k Popularity
- Pin
- Welcome Kevin_Lee to the Gate Square! 🎉
Looking forward to more great crypto insights from him.
Check out and engage with Kevin_Lee’s latest post!
👉 Post: https://www.gate.com/post/status/11758920
👉 Profile: https://www.gate.com/profile/Kevin%20Lee
Let’s give Kevin_Lee a warm welcome! 👏👏👏
- 🎯 LOT Newcomer Limited-Time Airdrop is Live!
Individual users can earn up to 1,000 LOT — share from a total prize pool of 1,000,000 LOT!
🏃 Join now: https://www.gate.com/campaigns/1294
Complete deposit and trading tasks to receive random LOT airdrops. Exclusive Alpha trading task await!🎯 LOT Newcomer Limited-Time Airdrop is Live!
Individual users can earn up to 1,000 LOT — share from a total prize pool of 1,000,000 LOT!
🏃 Join now: https://www.gate.com/campaigns/1294
Complete deposit and trading tasks to receive random LOT airdrops. Exclusive Alpha trading task await!
- 🎯 How to Earn Content Mining Rewards on Gate Post?
1️⃣ Create a post on Gate Post
2️⃣ Get likes or comments from other users
3️⃣ If those users trade (spot or futures) shortly after engaging with your post...
💰 You earn up to 10% commission on their trading fees!
📢 Share ✍️ Engage 💬 Earn 💰
- 🚀 Gate Square Creator Spark Program is Live!
We're officially recruiting the first batch of creators on Gate Square! Whether you're a crypto KOL, project team, or media outlet, join now and enjoy:
💰 Over $10,000 in monthly posting rewards
📣 Exposure to millions of Gate users
📢 Featured promotion and official support
🔥 Don't miss this early-mover advantage — apply now 👉 https://www.gate.com/questionnaire/6819
📄 More info 👉 https://www.gate.com/announcements/article/45695 - 🎉 Gate Alpha Second Points Special Airdrop is coming!
Get Token Mystery Boxes based on your Alpha Points - No points will be deducted.
📸 Alpha Points Snapshot: June 24, 16:00 (UTC)
Multi-chain trading now supported — buy on-chain assets directly with USDT!
🔗 Full details: https://www.gate.com/announcements/article/45683
Global Real-World Study Results of the Largest-scale JAK1 Inhibitor Released
On March 8th, Jinshi Data reported that at the recent AAD meeting in the United States, the interim results of the world's largest JAK1 inhibitor, Abrocitinib, in the real world study AHEAD (Abrocitinib CHinese rEgistry on AD) were internationally released. This provides more real-world research and medical evidence data for the innovative small molecule drug with high selectivity JAK1 inhibitor in the field of atopic dermatitis (AD), further strengthening the clinical scientific basis to optimize treatment strategies and drive the reshaping of AD diagnosis and treatment pathways.